OOIR: Observatory of International Research

Papers

(The TQCC of Melanoma Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study	50
Rurality as a predictor of melanoma stage and treatment in Indiana: a retrospective cohort study	36
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting	26
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	25
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	23
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	19
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?	19
CTLA-4 and TNFRSF1B genetic variants in clinicopathological aspects and outcome of cutaneous melanoma	18
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases	18
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases	18
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	16
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection	15
Chromosome 1p13.2 gene cluster upregulation in neuroblastoma RAS viral oncogene homolog pathogenic variant melanoma: a potential biomarker axis	14
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy	13
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study	13
Real-world recurrence-free and distant metastasis-free survival in early-stage melanoma: concordance with KEYNOTE-716 trial estimates	13
Brain metastases during follow-up of patients with resected cutaneous melanoma	13
Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study	12
Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors	12
Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis	11
Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy	10
Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors	10
Immunotherapy-induced granulomatous reaction in patients with melanoma	10
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient	9
Divergent pathways of melanoma development: evidence from a Southern European cohort	8

Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma	8
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma	8
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma	8
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum	8
Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma	8
Ultraviolet A radiation exposure and melanoma: a review	8
Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy	8
Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors	7
Multiple melanoma, ichthyosis, and juvenile cataracts in a patient with a germline mutation in CDKN2A: pure coincidence or related association?	7
Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients	7
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study	6
Novel uveal melanoma patient-derived cell line and organoid models show increased treatment resistance compared with commercially available cell lines	6
Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study	6
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	6
Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis	6
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series	6
Safety of tranexamic acid in patients with stage III melanoma undergoing lymph node dissection: a retrospective cohort study	6
Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporti	6
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight	6
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity	5
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis	5
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature	5
Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to	5
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	5
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	5
Immune-related cholecystitis following combination therapy with nivolumab and ipilimumab in a patient with metastatic melanoma: a case report and literature review	5
Expression and prognostic value of cyclase-associated proteins in cutaneous melanoma	5
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins	5
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II	4
Melanoma risk during immunomodulating treatment	4
Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update	4
Survival and toxicity profile of elderly melanoma patients treated with immune checkpoint inhibitors: a retrospective study from a tertiary care center	4
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment	4
Simultaneous melanomas in the setting of multiple primary melanomas	4
Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observation	4
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	4
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	4
Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies	4
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition	4
Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma	4
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma	4
Tebentafusp-associated dermatological adverse events in patients with metastatic uveal melanoma: a single-center retrospective cohort study	4
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	4
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma	4
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	4
Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials	4
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety	4
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	4